hydroxychloroquine has been researched along with Nephritis in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Nephritis: Inflammation of any part of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an antimalarial drug with known immunomodulatory, anti-inflammatory, and autophagy inhibitory effects; it is recognized in the treatment of autoimmune diseases such as systemic lupus erythematosus." | 5.91 | Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling. ( Inoue, H; Kinoshita, A; Koji, T; Mukae, H; Nishino, T; Obata, Y; Torigoe, K; Torigoe, M, 2023) |
| "Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities." | 1.91 | Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. ( Craigo, S; Kuller, JA; Norton, ME; Osmundson, SS; Porter, F; Silver, R, 2023) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug with known immunomodulatory, anti-inflammatory, and autophagy inhibitory effects; it is recognized in the treatment of autoimmune diseases such as systemic lupus erythematosus." | 1.91 | Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling. ( Inoue, H; Kinoshita, A; Koji, T; Mukae, H; Nishino, T; Obata, Y; Torigoe, K; Torigoe, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silver, R | 1 |
| Craigo, S | 1 |
| Porter, F | 1 |
| Osmundson, SS | 1 |
| Kuller, JA | 1 |
| Norton, ME | 1 |
| Torigoe, M | 1 |
| Obata, Y | 1 |
| Inoue, H | 1 |
| Torigoe, K | 1 |
| Kinoshita, A | 1 |
| Koji, T | 1 |
| Mukae, H | 1 |
| Nishino, T | 1 |
2 other studies available for hydroxychloroquine and Nephritis
| Article | Year |
|---|---|
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Wei | 2023 |
Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling.
Topics: Animals; Anti-Inflammatory Agents; Glomerulonephritis; Hydroxychloroquine; Male; Nephritis; p38 Mito | 2023 |